Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Working Knowledge
Business Research for Business Leaders
  • Browse All Articles
  • Popular Articles
  • Cold Call Podcast
  • Managing the Future of Work Podcast
  • About Us
  • Book
  • Leadership
  • Marketing
  • Finance
  • Management
  • Entrepreneurship
  • All Topics...
  • Topics
    • COVID-19
    • Entrepreneurship
    • Finance
    • Gender
    • Globalization
    • Leadership
    • Management
    • Negotiation
    • Social Enterprise
    • Strategy
  • Sections
    • Book
    • Podcasts
    • HBS Case
    • In Practice
    • Lessons from the Classroom
    • Op-Ed
    • Research & Ideas
    • Research Event
    • Sharpening Your Skills
    • What Do You Think?
    • Working Paper Summaries
  • Browse All
    The Impact of the Entry of Biosimilars: Evidence from Europe
    26 Jul 2016Working Paper Summaries

    The Impact of the Entry of Biosimilars: Evidence from Europe

    by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern
    Biosimilars are large-molecule drugs that, while not an exact copy of already-approved large-molecule drugs, have been shown to be therapeutically equivalent. Much like generic drugs, which become available when a small-molecule drug goes off patent, biosimilars are lower in cost than their reference products and present an opportunity for savings when large-molecule drugs’ patents expire. Biosimilars have been available in the United States only since 2015 but have been regulated, approved, and sold in Europe for over a decade. This paper examines the European experience to help inform policy design and institutional choices for the United States. Topics covered include the entry of distributors and unique products; predictors of average product prices following biosimilar competition; and penetration of biosimilars as a share of total sales.
    LinkedIn
    Email

    Author Abstract

    Biologic (large-molecule) drugs represent a disproportionate and growing share of all drug spending in the United States, accounting for less than 1 percent of prescriptions filled but nearly 28 percent of drug spending. Whereas traditional (small-molecule) drugs have historically faced price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already approved biologic drug—have only been approved in the United States since 2015. Europe has had biosimilar entry since 2006. This paper considers how competition from biosimilars may impact the U.S. biosimilar market by examining data from the first eight years of biosimilar competition in 23 European countries. A major contribution of this project is the completion of a detailed survey, allowing us to precisely characterize European biologic drug procurement institutions over time. Using data from three classes of biosimilar drugs, we analyze how market features and public polices predict entry, market prices, and penetration of biosimilars. We find significant heterogeneity across countries and drug classes in all of these outcomes. While we observe that effective buyer institutions (in particular, committed tenders) are associated with increased biosimilar entry and penetration, price patterns are more difficult to glean from the available data. Our estimates can inform ongoing policy discussions on both sides of the Atlantic about the economic implications of biosimilar policies.

    Paper Information

    • Full Working Paper Text
    • Working Paper Publication Date: June 2016
    • HBS Working Paper Number: 16-141
    • Faculty Unit(s): Technology and Operations Management
      Trending
        • 17 Mar 2022
        • Research & Ideas

        Navigating Tradeoffs: How Purpose Becomes a Company's ‘Lighthouse in the Storm’

        • 13 Jun 2022
        • Research & Ideas

        Extroverts, Your Colleagues Wish You Would Just Shut Up and Listen

        • 30 Jun 2022
        • HBS Case

        Peloton Changed the Exercise Game. Can the Company Push Through the Pain?

        • 25 Jan 2022
        • Research & Ideas

        More Proof That Money Can Buy Happiness (or a Life with Less Stress)

        • 18 Apr 2022
        • HBS Case

        Dick’s Sporting Goods Followed Its Conscience on Guns—and It Paid Off

    Ariel D. Stern
    Ariel D. Stern
    Poronui Associate Professor of Business Administration
    Contact
    Send an email
    → More Articles
    Find Related Articles
    • Research and Development
    • Policy
    • Governing Rules, Regulations, and Reforms
    • Health
    • Biotechnology
    • Pharmaceutical
    • United States

    Sign up for our weekly newsletter

    Interested in improving your business? Learn about fresh research and ideas from Harvard Business School faculty.
    ǁ
    Campus Map
    Harvard Business School Working Knowledge
    Baker Library | Bloomberg Center
    Soldiers Field
    Boston, MA 02163
    Email: Editor-in-Chief
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College